Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13548MR)

This product GTTS-WQ13548MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13548MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1280MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ3084MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ7820MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ8221MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ811MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ2072MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ4462MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ9333MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW